CPC A61K 31/737 (2013.01) [A61K 9/0043 (2013.01); A61K 9/08 (2013.01); A61K 31/164 (2013.01); A61K 31/197 (2013.01); A61K 35/747 (2013.01); A61K 35/748 (2013.01); A61K 36/03 (2013.01); A61K 36/04 (2013.01); A61K 36/53 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01)] | 25 Claims |
1. A method for treating a respiratory tract and/or respiratory mucosal-related condition in a subject in need thereof, comprising aerosolizing a pharmaceutical nasal spray composition in a nasal passageway of the subject wherein the pharmaceutical nasal spray composition comprises:
an ionic aqueous solution; and
a sulfated polysaccharide that is substantially free of proteins or cellular material, having an average molecular weight of from about 4 kDa to about 5 MDa and comprising L-fucose and sulfate ester groups, wherein:
i) the ionic aqueous solution comprises filtered or sterilized seawater;
ii) the sulfated polysaccharide is in a range of about 0.1 to less than 1% weight content of the composition;
iii) the sulfated polysaccharide is purified from an extract isolated from brown algae; and
iv) said composition is hypertonic and has an osmolarity value greater than 350 mOsm/L.
|